An increasing awareness of the dangers of opioid pain relief in the US healthcare system has provided an opening for NZX-listed drug maker AFT Pharmaceuticals, which today announced it has signed an almost US$19 million deal to supply its main product Maxigesic for use in hospital IV systems in the
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
